Optimal treatment of renal anaemia (OPTA): Improving the efficacy and efficiency of renal anaemia therapy in haemodialysis patients receiving intravenous epoetin

Nephrology Dialysis Transplantation

Volumn 20, Issue SUPPL. 3, 2005, Pages

  Hörl, Walter H ^a   Vanrenterghem, Yves ^b   Canaud, Bernard ^b   Mann, Johannes ^b   Teatini, Ugo ^b   Wanner, Christoph ^b   Wikström, Björn ^b  

^a Klinische Abteilung Fr Nephrologie und Dialyse   (Austria)

^b NONE

Author keywords

Epoetin; Haemodialysis; Infection; Inflammation; Iron; Renal anaemia

Indexed keywords

ALPHA TOCOPHEROL; ANDROGEN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIMETABOLITE; ASCORBIC ACID; AZATHIOPRINE; CARNITINE; CYANOCOBALAMIN; CYTOKINE ANTIBODY; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOLIC ACID; GROWTH HORMONE; HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRON; LOW MOLECULAR WEIGHT HEPARIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PYRIDOXINE; RECOMBINANT ERYTHROPOIETIN; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ZINC;

ANEMIA; ARTICLE; BLEEDING; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HEALTH SURVEY; HEMODIALYSIS; HEMODIALYSIS PATIENT; HOSPITALIZATION; HUMAN; INFECTION; INFLAMMATION; IRON DEFICIENCY; KIDNEY FAILURE; MALIGNANT NEOPLASTIC DISEASE; MALNUTRITION; MORBIDITY; MORTALITY; OXALOSIS; PRIORITY JOURNAL; QUALITY OF LIFE; SECONDARY HYPERPARATHYROIDISM;

AGED; ANEMIA; ERYTHROPOIETIN, RECOMBINANT; HEALTH PLANNING GUIDELINES; HEMATINICS; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 19044370225     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh1071     Document Type: Article

References (70)

1. Revised European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. Nephrol Dial Transplant 2004; 19 [Suppl 2]: ii1-ii47
2. IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. Am J Kidney Dis 2001; 37: S182-S238
3. Jacobs C, Hörl WH, Macdougall IC et al. European best practice guidelines 9-13: anaemia management. Nephrol Dial Transplant 2000; 15 [Suppl 4]: 33-42
4. Pisoni RL, Bragg-Gresham JL, Young EW et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004; 44: 94-111
5. Hecking E, Bragg-Gresham JL, Rayner HC et al. Haemodialysis prescription, adherence and nutritional indicators in five European countries: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004; 19: 100-107
6. Locatelli F, Pisoni RL, Combe C et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004; 19: 121-132
7. Richardson D. Clinical factors influencing sensitivity and response to epoetin. Nephrol Dial Transplant 2002; 17 [Suppl 1]: 53-59
8. European Best Practice Guidelines Expert Group on Hemodialysis, European Renal Association. Section II. Hemodialysis adequacy. Nephrol Dial Transplant 2002; 17 [Suppl 7]: 16-31
9. I. NKF-K/DOQI Clinical Practice Guidelines for Hemodialysis Adequacy: update 2000. Am J Kidney Dis 2001; 37: S7-S64
10. Eknoyan G, Beck GJ, Cheung AK et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347: 2010-2019
11. Kotanko P. Intensity of hemodialysis and response to erythropoietin. N Engl J Med 1996; 334: 1670
12. Kawano Y, Takaue Y, Kuroda Y, Minkuchi J, Kawashima S. Effect of alleviation of renal anemia by hemodialysis using the high-flux dialyzer (BK-F). Kidney Dial 1994; 35: 200-203
13. Locatelli F, Andrulli S, Pecchini F et al. Effect of high-flux dialysis on the anaemia of haemodialysis patients. Nephrol Dial Transplant 2000; 15: 1399-1409
14. Locatelli F. Optimizing dose and mode of renal replacement therapy in anaemia management. Nephrol Dial Transplant 2002; 17 [Suppl 5]: 60-65
15. Pontoriero G, Pozzoni P, Andrulli S, Locatelli F. The quality of dialysis water. Nephrol Dial Transplant 2003; 18 [Suppl 7]: vii21-vii25
16. Section IV. Dialysis fluid purity. Nephrol Dial Transplant 2002; 17 [Suppl 7]: 45-62
17. Lucchi L, Bergamini S, Botti B et al. Influence of different hemodialysis membranes on red blood cell susceptibility to oxidative stress. Artif Organs 2000; 24: 1-6
18. Bommer J, Gemsa D, Waldherr R, Kessler J, Ritz E. Plastic filing from dialysis tubing induces prostanoid release from macrophages. Kidney Int 1984; 26: 331-337
19. Leong AS, Disney AP, Gove DW. Spallation and migration of silicone from blood-pump tubing in patients on hemodialysis. N Engl J Med 1982; 306: 135-140
20. European Best Practice Guidelines Expert Group on Hemodialysis, European Renal Association. Section III. Biocompatibility. Nephrol Dial Transplant 2002; 17 [Suppl 7]: 32-44
21. Macdougall IC. Poor response to erythropoietin: practical guidelines on investigation and management. Nephrol Dial Transplant 1995; 10: 607-614
22. Hocken AG. Iron losses in haemodialysis patients. Lancet 1971; 2: 662
23. Hocken AG, Marwah PK. Iatrogenic contribution to anaemia of chronic renal failure. Lancet 1971; 1: 164-165
24. Ifudu O, Feldman J, Friedman EA. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. N Engl J Med 1996; 334: 420-425
25. Otti T, Khajehdehi P, Fawzy A, Gellens M, Bastani B. Comparison of blood loss with different high-flux and high-efficiency hemodialysis membranes. Am J Nephrol 2001; 21: 16-19
26. Sunder-Plassmann G, Hörl WH. Safety aspects of parenteral iron in patients with end-stage renal disease. Drug Safety 1997; 17: 241-250
27. Fishbane S, Kowalski EA. The comparative safety of intravenous iron dextran, iron saccharate, and sodium ferric gluconate. Semin Dial 2000; 13: 381-384
28. Fishbane S, Wagner J. Sodium ferric gluconate complex in the treatment of iron deficiency for patients on dialysis. Am J Kidney Dis 2001; 37: 879-883
29. Yee J, Besarab A. Iron sucrose: the oldest iron therapy becomes new. Am J Kidney Dis 2002; 40: 1111-1121
30. Patruta SI, Edlinger R, Sunder-Plassmann G, Hörl WH. Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol 1998; 9: 655-663
31. Deicher R, Ziai F, Cohen G, Mullner M, Hörl WH. High-dose parenteral iron sucrose depresses neutrophil intracellular killing capacity. Kidney Int 2003; 64: 728-736
32. Sengoelge G, Kletzmayr J, Ferrara I, Perschl A, Hörl WH, Sunder-Plassmann G. Impairment of transendothelial leukocyte migration by iron complexes. J Am Soc Nephrol 2003; 14: 2639-2644
33. Drüeke T, Witko-Sarsat V, Massy Z et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 2002; 106: 2212-2217
34. Shah SV, Alam MG. Role of iron in atherosclerosis. Am J Kidney Dis 2003; 41: S80-S83
35. Aronoff GR, Bennett WM, Blumenthal S et al. Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens. Kidney Int 2004; 66: 1193-1198
36. Schrader J, Stibbe W, Armstrong VW et al. Comparison of low molecular weight heparin to standard heparin in hemodialysis/hemofiltration. Kidney Int 1988; 33: 890-896
37. Bambauer R, Rucker S, Weber U, Kohler M. Comparison of low molecular weight heparin and standard heparin in hemodialysis. ASAIO Trans 1990; 36: M646-M649
38. Spinowitz BS, Arslanian J, Charytan C, Golden RA, Rascoff J, Galler M. Impact of epoetin beta on dialyzer clearance and heparin requirements. Am J Kidney Dis 1991; 18: 668-673
39. Norton J, Spiezio R, LaManna L, DeLorme B. Varying heparin requirements in hemodialysis patients receiving erythropoietin. ANNA J 1992; 19: 367-372
40. Taylor JE, Belch JJ, McLaren M, Henderson IS, Stewart WK. Effect of erythropoietin therapy and withdrawal on blood coagulation and fibrinolysis in hemodialysis patients. Kidney Int 1993; 44: 182-190
41. Veys N, Vanholder R, De Cuyper K, Ringoir S. Influence of erythropoietin on dialyzer reuse, heparin need, and urea kinetics in maintenance hemodialysis patients. Am J Kidney Dis 1994; 23: 52-59
42. Clyne N, Lins LE, Egberg N. Long-term effects of erythropoietin treatment on the coagulation system during standardized hemodialysis. Clin Nephrol 1995; 43: 260-267
43. European Best Practice Guidelines Expert Group on Hemodialysis, European Renal Association. Section V. Chronic intermittent haemodialysis and prevention of clotting in the extracorporal system. Nephrol Dial Transplant 2002; 17 [Supp 7]: 63-71
44. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648-658
45. Iseki K, Tozawa M, Yoshi S, Fukiyama K. Serum C-reactive protein (CRP) and risk of death in chronic dialysis patients. Nephrol Dial Transplant 1999; 14: 1956-1960
46. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000; 35: 469-476
47. Stenvinkel P, Wanner C, Metzger T et al. Inflammation and outcome in end-stage renal failure: does female gender constitute a survival advantage? Kidney Int 2002; 62: 1791-1798
48. Ikizler TA, Wingard RL, Harvell J, Shyr Y, Hakim RM. Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: a prospective study. Kidney Int 1999; 55: 1945-1951
49. European Best Practice Guidelines Expert Group on Hemodialysis, European Renal Association. Section VII. Vascular disease and risk factors. Nephrol Dial Transplant 2002; 17 [Suppl 7]: 88-109
50. Hörl W, Jacobs C, Macdougall IC et al. European best practice guidelines 14-16: inadequate response to epoetin. Nephrol Dial Transplant 2000; 15 [Suppl 4]: 43-50
51. Nitta K, Akiba T, Takei T et al. Inflammation and resistance to erythropoietin in hemodialysis patients. Acta Haematol 2002; 108: 168-170
52. Macdougall IC, Cooper AC. Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant 2002; 17 [Suppl 11]: 39-43
53. Kalantar-Zadeh K, McAllister CJ, Lehn RS, Lee GH, Nissenson AR, Kopple JD. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis 2003; 42: 761-773
54. Drüeke TB, Eckardt KU. Role of secondary hyperparathyroidism in erythropoietin resistance of chronic renal failure patients. Nephrol Dial Transplant 2002; 17 [Suppl 5]: 28-31
55. Alon DB, Chaimovitz C, Dvilansky A et al. Novel role of 1,25(OH)(2)D(3) in induction of erythroid progenitor cell proliferation. Exp Hematol 2002; 30: 403-409
56. Melendez O. Intravenous vitamin C for erythropoietin resistance. Semin Dial 2000; 13: 335-336
57. Tarng DC, Huang TP. A parallel, comparative study of intravenous iron versus intravenous ascorbic acid for erythropoietin-hyporesponsive anaemia in haemodialysis patients with iron overload. Nephrol Dial Transplant 1998; 13: 2867-2872
58. Keven K, Kutlay S, Nergizoglu G, Erturk S. Randomized, crossover study of the effect of vitamin C on EPO response in hemodialysis patients. Am J Kidney Dis 2003; 41: 1233-1239
59. Hörl WH. Is there a role for adjuvant therapy in patients being treated with epoetin? Nephrol Dial Transplant 1999; 14 [Suppl 2]: 50-60
60. Hörl WH. Adjunctive therapy in anaemia management. Nephrol Dial Transplant 2002; 17 [Suppl 5]: 56-59
61. Morena M, Cristol JP, Bosc JY et al. Convective and diffusive losses of vitamin C during haemodiafiltration session: a contributive factor to oxidative stress in haemodialysis patients. Nephrol Dial Transplant 2002; 17: 422-427
62. Deicher R, Ziai F, Habicht A, Bieglmayer C, Schillinger M, Hörl WH. Vitamin C plasma level and response to erythropoietin in patients on maintenance haemodialysis. Nephrol Dial Transplant 2004; 19: 2319-2324
63. Cristol JP, Bosc JY, Badiou S et al. Erythropoiefin and oxidative stress in haemodialysis: beneficial effects of vitamin E supplementation. Nephrol Dial Transplant 1997; 12: 2312-2317
64. Galli F, Rovidati S, Chiarantini L et al. Bioreactivity and biocompatibility of a vitamin E-modified multi-layer hemodialysis filter. Kidney Int 1998; 54: 580-589
65. Nemeth I, Turi S, Haszon I, Bereczki C. Vitamin E alleviates the oxidative stress of erythropoietin in uremic children on hemodialysis. Pediatr Nephrol 2000; 14: 13-17
66. Hurot JM, Cucherat M, Haugh M, Fouque D. Effects of L-carnitine supplementation in maintenance hemodialysis patients: a systematic review. J Am Soc Nephrol 2002; 13: 708-714
67. Deicher R, Hörl WH. Hormonal adjuvants for the treatment of renal anemia. Eur J Clin Invest 2005; in press
68. Barton Pai A, Chretien C, Lau AH. The effects of nandrolone decanoate on nutritional parameters in hemodialysis patients. Clin Nephrol 2002; 58: 38-46
69. Viidas U, Johannsson G, Mattson-Hulten L, Ahlmen J. Lipids, blood pressure and bone metabolism after growth hormone therapy in elderly hemodialysis patients. J Nephrol 2003; 16: 231-237
70. Maisonneuve P, Agodoa L, Gellert R et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 1999; 354: 93-99